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REVIEW CURRENTOPINION Persistent HIV-1 replication during antiretroviral
therapy1746-630X Copyright  2016 Woltea,b,c dJavier Martinez-Picado and Steven G. DeeksPurpose of review
The present review will highlight some of the recent findings regarding the capacity of HIV-1 to replicate
during antiretroviral therapy (ART).
Recent findings
Although ART is highly effective at inhibiting HIV replication, it is not curative. Several mechanisms
contribute to HIV persistence during ART, including HIV latency, immune dysfunction, and perhaps
persistent low-level spread of the virus to uninfected cells (replication). The success in curing HIV will
depend on efficiently targeting these three aspects. The degree to which HIV replicates during ART
remains controversial. Most studies have failed to find any evidence of HIV evolution in blood, even with
samples collected over many years, although a recent very intensive study of three individuals suggested
that the virus population does shift, at least during the first few months of therapy. Stronger but still not
definitive evidence for replication comes from a series of studies in which standard regimens were
intensified with an integration inhibitor, resulting in changes in episomal DNA (blood) and cell-associated
RNA (tissue). Limited drug penetration within tissues and the presence of immune sanctuaries have been
argued as potential mechanisms allowing HIV to spread during ART. Mathematical models suggest that
HIV replication and evolution is possible even without the selection of fully drug-resistant variants. As
persistent HIV replication could have clinical consequences and might limit the efficacy of curative
interventions, determining if HIV replicates during ART and why, should remain a key focus of the
HIV research community.
Summary
Residual viral replication likely persists in lymphoid tissues, at least in a subset of individuals. Abnormal
levels of immune activation might contribute to sustain virus replication.
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In a motivated HIV-1-infected person who can
adhere to modern regimens indefinitely, a combi-
nation of optimally selected antiretroviral drugs
can suppress HIV-1 replication to levels below
which drug resistance cannot accumulate. As a
consequence, these drugs work indefinitely. It is
now widely assumed that a modern combination
regimen used optimally will work for decades and
that the life-time risk of treatment failure because of
drug resistance is negligible. Indeed, as drug resist-
ance is now so rarely encountered in the clinic, most
have assumed that ART is able to completely and
indefinitely suppress all replication. This assump-
tion is increasingly being challenged, however, and
the degree to which ART is fully suppressive is the
focus of ongoing debate and investigation.rs Kluwer Health, Inc. All rights reserved. www.co-hivandaids.com
KEY POINTS
 Although ART is highly effective at inhibiting HIV
replication, it is not curative. The degree to which HIV
replicates during ART remains controversial.
 Limited drug penetration within tissues, and the
presence of immune sanctuaries have been argued as
potential mechanisms allowing HIV to spread
during ART.
 As persistent HIV replication could have clinical
consequences and might limit the efficacy of curative
interventions, determining if HIV replicates during ART
and why, should remain a key focus of the HIV
research community.
Strategies for targeting residual HIV infectionAll antiretroviral drugs work by preventing the
capacity of HIV-1 to replicate, which can be defined
as the spread of infectious virus from one cell to
another cell. These drugs do not target integrated
HIV-1 DNA nor are they able to eliminate long-lived
cells that harbor these integrants. Accordingly, even
if ART is fully suppressive, the virus will persist for
decades, and be the source of recrudescent virus if
therapy is stopped. ART is not curative.
We believe that there are three major pathways
that should be investigated and targeted if we aim to
find a cure or, more precisely, a remission: residual
low-level viral replication, immune dysfunction,
and latency. The prevailing consensus is that ART
is highly effective at preventing HIV-1 replication,
moderately effective at reversing immune dysfunc-
tion, and mostly ineffective at clearing cells harbor-
ing latent HIV-1. The most stubborn barrier in
developing a cure will almost certainly prove to
be HIV-1 latency; most active cure programs are
understandably focused on reversing latency and
eliminating the virus producing cells (‘shock and
kill’). However, this approach assumes that all HIV-1
replication is completely inhibited and that ART is
so effective that it will inhibit even a resurgent virus
population that emerges in the context of a latency
reversing therapy. It is hence critically important to
determine the degree to which HIV-1 replication
persists during ART.
There is an open controversy as to whether
HIV-1 continues to replicate during ART. Some of
this debate is because of a lack of consensus regard-
ing the term replication. Some have argued that the
continued production of HIV-1 from an infected cell
is evidence of replication. As viremia persists at low
levels during ART, it is abundantly clear that virus
production persists indefinitely. We and others have
argued that the presence of viral particles in cells
or plasma is not proof that the virus is actively418 www.co-hivandaids.comspreading to new target cells. As we discuss in this
review, there are ample data to support the thesis
that ART is fully effective at blocking replication.
There is also ample and we argue more persuasive
data that the virus does indeed continue to replicate,
albeit at low levels and perhaps only in a subset
of individuals.MEASURING HIV-1 REPLICATION DURING
ANTIRETROVIRAL THERAPY
Although there are multiple approaches to measure
the reservoir of HIV-1 in plasma, cells, and tissues,
none is able to directly determine if the virus is
actively replicating. In the absence of ART, the
standard way to estimate the total body rate
of HIV-1 replication is to determine the plasma
HIV-1 RNA level. At steady state, the level of viremia
is a reasonable estimate of the number of virus-
producing cells and presumably the level of repli-
cation [1]. This is assumed to be true even in states
of immunologic control. Among those controlling
HIV-1 in absence of therapy (‘elite controllers’),
there exists a steady-state level of viremia [2] and
a persistent reservoir of replication-competent virus
that enables continued replication [3–5]. Among
controllers with low or undetectable plasma HIV-1
RNA levels, the presence of persistent viremia
almost certainly reflects, in part, active replication,
as shown by recent studies in which controllers were
given ART [5].
A steady-state level of very-low viremia has also
been described among those on ART [6,7], but it is
far less clear if active HIV-1 replication contributes
to viremia during ART. The molecular nature of such
techniques does not allow us to determine whether
residual virus are infectious or not, but their long-
term persistence (over 7 years) suggests that they are
at least being produced over time, and not just
released from trapped stages in certain cells. The
genetic structure of virus population during ART





ongoing cycles of HIV-1 replication, although
recent data have challenged this assumption
[13
&&
], as discussed below.
Given the lack of any direct methods to quantify
replication in vivo, we and others have used
treatment intensification of standard regimens to
determine if more potent ART can alter the size of
the reservoir. With regard to plasma HIV-1 RNA, the
results of these studies have been very consistent.
Adding a potent antiretroviral drug to a stable
regimen has no measurable impact on plasma
HIV-1 RNA levels [14–21], strongly suggesting that
ongoing cycles of HIV-1 replication are not a major
mechanism for persistent viremia during ART.Volume 11  Number 4  July 2016
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integrase inhibitor drug class allowed us, and others,
to indirectly assess replication during ART. These
drugs inhibit the integration of episomal HIV-1
DNA strands– including two-long terminal repeat
(2-LTR) circles – into host genome. In two random-
ized clinical trials of HIV-1-infected adults on appa-
rently effective ART, the addition of an integrase
inhibitor (raltegravir) to a stable regimen resulted in
a transient increase in 2-LTR-circles, suggesting that
HIV-1 integration had been blocked [22,23]. A
transient increase in episomal DNA with inhibition
of integration suggests that at baseline (preintensi-
fication), there existed a steady-state in which there
were going cycles of HIV-1 DNA integration; this in
turn implies that at steady-state, HIV-1 was being
successfully spread from one cell to the next, with
RNA being successfully reversed transcribed (despite
the presence of reverse transcriptase inhibitors) and
the newly produced DNA eventually being success-
fully integrated (i.e. a complete round of replica-
tion). Interrupting this cycle at steady state would
be expected to result in a transient and early increase
in the preintegrated episomes, as observed in both
studies. Of note, this phenomenon was only
observed in about one-third of subjects, with most
of the activity observed in those who had been on a
protease inhibitor-based regimen.
Whether transiently produced 2-LTR circles are
the result of ongoing cycles of viral replication or
just persistent viral release from productively
infected cells is debatable. However, mathematical
modeling of the data suggests that the transient
dynamics of 2-LTR after intensification with
integrase inhibitors would be more compatible with
the former hypothesis [24]. Of note, similar 2-LTR
dynamics are also observed in patients who initiate
ART with integrase inhibitors [25]. Notably, over
time, integrase inhibitor intensification results
in lower levels of CD8þ T-cell activation [18] and
D-dimers [23], an outcome which strongly suggests
that low-level replication had been occurring.
Moreover, when integrase inhibitor intensification
was discontinued, CD8þ T-cell activation levels
increased in patients who had shown increases in
2-LTR circles [26].
Preliminary viral genetic analysis suggested
that cells sequestered in tissues rather than circulat-
ing T cells were supporting virus replication [27].
Subsequent spatial modeling suggests that con-
ditions for the formation of an observed transient
peak in 2-LTR formation following raltegravir
intensification include a sanctuary site diameter
larger than 0.2 mm, a viral basic reproductive
ratio within the site larger than 1, and a total
volume of active sanctuary sites above 20 ml [28].1746-630X Copyright  2016 Wolters Kluwer Health, Inc. All rights reseHowever, treatment intensification therapy has
not contributed to reduce the total number of
HIV-1-infected cells [22].
The exploration of candidate molecules target-
ing viral reactivation has promoted the use of
cell-associated HIV-1 RNA as a way to measure the
pharmacological impact of those molecules to flush
HIV-1 out of the host genome. Interestingly, the
levels of HIV-1 transcription has been greater than
expected, even in resting memory CD4þ T cells,
which were considered to be transcriptionally silent
[12
&
]. Although it is clear that viral transcription
does not imply generation of mature infectious
virions [29], it is intriguing to observed such a basal
production of unspliced viral RNA. In fact, it has
been reported that higher levels of HIV-1 expression
while on ART are associated with shorter time
to HIV-1 rebound after treatment interruption,
suggesting that quantification of the active HIV-1
reservoir may provide a biomarker of efficacy for
therapies that aim to achieve ART-free HIV-1 remis-
sion [30
&&
]. Raltegravir-containing ART intensifica-
tion has been shown to reduce the detection of
unspliced HIV-1 RNA in CD4þ T cells in the terminal
ileum, suggesting that this gut site might support
ongoing productive infection in some patients on
ART, even if the contribution to plasma RNA is not
discernible [31].MEASURING HIV-1 EVOLUTION DURING
ANTIRETROVIRAL THERAPY
If, as suggested by the aforementioned studies,
HIV-1 is replicating during ART, then it is reasonable
to assume that the virus would continue to evolve.
Among individuals with natural control of viral
replication (‘elite controllers’), virus evolution
can be readily detected [3,32]. Detecting HIV-1
evolution during ART has been difficult. Indeed,
the characterization of HIV-1 genetic sequences in
the majority of patients treated for up to 15 years
with suppressive ART has shown no detectable
HIV-1 molecular evolution, strongly arguing against





These studies relied largely on blood-based measure-
ments, a major limitation as most of the so-called
active reservoir is likely in tissues, in which cell-
to-cell transfer is theoretically more efficient [33].
Some teams, however, have reported evidence
of HIV-1 evolution during ART. Sequence evolution
consisting of new drug resistance mutations
and novel amino acid changes within a relevant
HLA-restricted allele were described during recombi-
nant HIV-1 poxvirus immunizations in patients
with clinically undetectable viral loads on durable
suppressive ART [34]. In a separate study, ultra-deeprved. www.co-hivandaids.com 419
Strategies for targeting residual HIV infectionsequencing of V3 env regions of viruses in peripheral
blood mononuclear cells of patients on long-term
suppressive ART revealed evolution of HIV-1
quasispecies in cell reservoirs and genetic diversifi-
cation of the virus in patients infected with
CXCR4-tropic viruses [35].
A recent intensive study of three HIV-infected
adults provides additional evidence for residual
evolution (and, by extension, replication) during
ART [13
&&
]. Deep sequencing methods were applied
to HIV-1 DNA obtained from lymph nodes at
baseline, month 3, and month 6 of ART. Although
drug resistance mutations did not accumulate, a
phylogenetic analysis revealed a temporal structure
consistent with ongoing evolution.
Mathematical modeling has been used to
better understand the mechanisms underlying
viral persistence in patients on suppressive ART.
Models that include stochastic population switch
may reconcile the coexistence of low viral load
persistence, emergence of intermittent viral blips
and stability of the latent reservoir [36
&
]. Similarly,
mathematical models of latently and productively
infected cells and virus predict that, in patients
on suppressive ART, the contribution of viral
replication to residual virus, whereas small, yields
short-term evolution [37
&&
]. But even if the contri-
bution is large (e.g. poor adherence to therapy),
long-term evolution can still be limited, and
de novo emergence of drug resistance remain rare.
Therefore, this theoretical approach attempts to
reconcile the seemingly contradictory experimen-










FIGURE 1. Suggested mechanisms of HIV residual replication
within tissues, the presence of immune sanctuaries, cell-to-cell vira
inflammation have been argued as potential mechanisms allowing
420 www.co-hivandaids.comMECHANISMS ENABLING HIV-1
REPLICATION DURING ANTIRETROVIRAL
THERAPY
The collective data strongly suggest that low-levels
of HIV-1 replication persist during ART, at least in
some individuals. Given that current antiretroviral
drugs are potent and should be able to fully block
HIV-1 spread [38–40], why would HIV-1 replication
persist?
It has also been proposed that cell-to-cell spread
of HIV-1 contributes to ongoing replication despite
ART [33]. In an in-vitro experimental model,
infections involving cell-to-cell spread were mark-
edly less sensitive to the drugs than infections
originating from cell-free virus, without requiring
drug-resistant mutations. Cell-to-cell viral transfer
has also been reported to contribute to HIV-1 infec-
tion and persistence in astrocytes [41
&
], suggesting
that decreased drug sensitivity in these contacts
might contribute to provide additional explanations
for the HIV-1 persistence in the central nervous
system where the access of antiretroviral drugs may
be limited. It remains to be proved, however, whether
cell-to-cell spread has the same properties in vivo.
It should be noted that cell-to-cell transmission
of HIV-1 efficiently triggers pyroptotic death
of lymphoid-tissue-derived CD4þ T cells [42
&&
]. If
antiretroviral drugs suboptimally inhibit cell-to-cell
HIV-1 transmission, inflammation and progressive
depletion of CD4þ T cells will still happen in spite
of suppressive plasma viremia (Fig. 1).
Theoretical considerations and some emerging
data suggest that the actively replication viral






during antiretroviral therapy (ART). Limited drug penetration
l transmission, and abnormal levels of immune activation and
HIV to spread and evolve during ART.
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successful infection events more likely [33]. The
distribution of antiretroviral drugs within lymphoid
tissues may also be a factor. In a recent study,
intracellular concentrations of the most antiretro-
viral drugs in peripheral blood mononuclear cells
did not predict concentrations in lymph node, ileal,
and rectal mononuclear cells. In fact, tissue concen-
trations of several of the most frequently used
antiretroviral drugs (including tenofovir disoproxil
fumarate, emtricitabine, efavirenz, atazanavir, and
darunavir) were lower than in peripheral blood
[43
&&
]. These lower concentrations correlated with
slower decay (and even possible increases) in the
follicular dendritic cell network pool of virions
and with detection of viral RNA in productively
infected cells. Other groups have failed to find
reduced concentrations of some of these and other
drugs within gut tissue [44,45], however, and
the potential mechanism accounting for reduced
antiretroviral drug penetration into lymphoid
tissues has not been identified.
The B-cell follicle within lymph nodes appears
to be a major site for active viral replication in
untreated simian immunodeficiency virus (SIV)
and HIV infection [46,47,48
&&
]. This is particularly
true in the context of strong host-mediated immune
control (‘elite’ control) and perhaps during ART
[48
&&
]. CD8þ T cells – the best characterized pathway
by which the immune system can effectively control
SIV/HIV – are excluded from the B-cell follicle
(presumably to allow more efficient interactions
between B cells and those cells which enable them
to mature, including a T follicular helper cells). The
lack of efficient CTL responses in these regions
may allow SIV/HIV replication in lymphoid tissue
[48
&&
,49,50], accounting for the low levels of viral




Infected macrophages and resident microglia in
the central nervous system serve as long-lived cellular
reservoirs of HIV-1. These cells are found to harbor
productive HIV-1, with perivascular macrophages
constituting the principle reservoir of productive virus
in the brain. Beyond the contribution of these long-
livedcells to the clinical development and progression
of HIV-1-associated neurocognitive disorders, they
also represent a major obstacle in virus eradication
that needs to be therapeutically targeted [51].CLINICAL IMPLICATIONS OF RESIDUAL
REPLICATION DURING ANTIRETROVIRAL
THERAPY
Residual viremia has also been linked with develop-
ment of blips and low-level viremia (50–1000 HIV-11746-630X Copyright  2016 Wolters Kluwer Health, Inc. All rights reseRNA copies/ml) in treated patients with HIV-1 [52].
In fact, replication-competent residual HIV-1 has
been recovered from the plasma of a patient receiv-
ing long-term suppressive ART, suggesting that
residual viruses produced in the absence of therapy
could initiate fresh cycles of infection and spread in
host cells [53]. Individuals with ultrasensitive
viremia above 2.5 HIV-1 RNA copies/ml had greater
plasma levels of lipopolysaccharide than those with
viremia below 2.5 copies/ml, indicating an associ-
ation between microbial translocation and residual
viral production if not replication [54]. Many studies
have found a positive association between the levels
of HIV-1 persistence and inflammation [55–59],
again suggesting these two phenomena are linked.
There likely exists a complex bi-directional
association between residual inflammation and
residual HIV-1 replication. Residual inflammation
may contribute to HIV-1 persistence by inducing
de-novo infection in activated CD4þ T cells and by
upregulating the expression of immune checkpoint
blockers and other immunoregulatory pathways
that blunt HIV-1-specific immune responses [60].
Persistent HIV-1 replication may in turn contribute
to an inflammatory environment [22,23]. Therefore,
it has been proposed that compounds addressed
to reduce immune activation and inflammation




The evidence of persistent replication in many if not
all HIV-1-infected individuals on ART argues for the
development and evaluation of novel therapeutic
strategies that will fully suppress viral replication.
Several approaches involve the implementation
of improved drugs on existing targets, new formu-
lations and delivery systems [63], new viral and cell
targets [64], the use of therapies based on neutraliz-
ing monoclonal antibodies [65–67], or chimeric
proteins as eCD4-Ig (a fusion of CD4-Ig with a
small CCR5-mimetic sulfopeptide) expressed in
adeno-associated virus vectors [68]. The goal of
these new approaches is not only to achieve excell-
ent potency but also improved drug penetration
and reduced toxicity. Moreover, these strategies
could also avert the long-term clinical consequences
of chronic immune activation driven directly or
indirectly by low-level viral replication to thereby
improve immune reconstitution.
Cutting-edge research is being performed in the
field of HIV-1 remission, including the development
of new technologies that should facilitate the detec-
tion of viral dynamics and localization in lymphoid
tissues. A new real-time, in-vivo viral imagingrved. www.co-hivandaids.com 421
Strategies for targeting residual HIV infectionmethod to capture total-body SIV replication using
antibody-targeted positron emission tomography
(immunoPET) has been applied to the detection




refinements to improve contrast and uptake,
this approach should be easily translatable to
humans because of the availability of anti-Env
HIV-1 antibodies and because the imaging approach
is based on technologies already used in the clinic.
It also provides the ability to identify novel areas
of virus replication that may otherwise be difficult
to sample during studies investigating the eradica-
tion of HIV infection. Comprehensive characteriz-
ation of HIV-1 antibody profiles has also been
suggested as a method to monitor curative
interventions [70].CONCLUSION
In summary, complete block of residual viral
replication is a prerequisite to successfully eliminat-
ing viral reservoir. Unfortunately, we lack a robust
assay that ensures the identification of an active
viral reservoir. Persistent levels of HIV-1 RNA in
plasma, below the limit of detection of clinical
assays, are difficult to interpret but suggestive of,
at least, sustained viral leaking. Viral replication
might also be confined to specific tissues and cell
types where drug concentrations might be sub-
optimal. There is an association between residual
viral replication and persistent immune activation
and inflammation; however, we lack a clear
immunological mechanism. The future imple-
mentation of new diagnostic tools and new treat-
ment strategies with improved profiles of potency
and tissue penetrability should facilitate the final
remission of HIV-1 infection.
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